This is a pivotal time in the history of cannabis and cannabinoid research. In the context of increasing debateson the merits of medical and recreational cannabis policies, we need a corresponding increase in cannabis research. Many advocates on either side of these debatesappear content to promote their agendas without placing priority on funding and supporting research thatwould answer key questions about the safety of cannabisand its potential medical indications. The often contentious debate about the efficacy of cannabis pharmacotherapy for pain is an important example. There isevidence, although limited, to support the use of cannabis pharmacotherapy in certain clinical scenarios. Forexample, if a patient with chronic pain and their healthcare provider work together through first- and secondline treatment modalities without success, a trial ofcannabis or a cannabinoid may be a reasonable nextstep. As cannabis use increases, additional research tosupport or refute the current evidence base is essentialto attempt to answer the questions that so many healthcare professionals and patients are asking